Adalimumab Concept

Vocabulary Service

MeSH

Overview

subject area of

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Academic Article
Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Academic Article
Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies Academic Article
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis Academic Article
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis Academic Article
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. Academic Article
Anti-TNFα therapy in immune-mediated subfertility: State of the art Academic Article
Bell's palsy in a patient receiving adalimumab for Crohn's disease Academic Article
Biologic survival. Academic Article
COMMENTARY: Should Anti-TNF-α Therapy be Offered to Patients with Infertility and Recurrent Spontaneous Abortion?* Academic Article
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study Academic Article
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Academic Article
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease Conference Paper
Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis Academic Article
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Academic Article
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis Academic Article
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab Academic Article
Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial Academic Article
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis Academic Article
Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab Academic Article
Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients Academic Article
Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease Academic Article
Immunotherapies in Dermatologic Disorders Academic Article
Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study Academic Article
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study Academic Article
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate Academic Article
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease Academic Article
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply Academic Article
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study Academic Article
Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease Academic Article
Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Academic Article
Patient outcomes after anti TNF-α drugs for Crohn’s disease Academic Article
Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics Academic Article
Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database Academic Article
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease Academic Article
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study Academic Article
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial Academic Article
The economics of adalimumab for ulcerative colitis Academic Article
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease Academic Article
Treatment of severe facial psoriasis with adalimumab. Academic Article
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Academic Article
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission Academic Article
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease Academic Article